Journal article · 2020 · Open access
Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
Psychiatric Research and Clinical Practice, 2(2), 76–87 · Published 29 June 2020 · DOI 10.1176/appi.prcp.20200004
In brief
“Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia” is a 2020 journal article by Marian S. McDonagh and 9 co-authors, published in Psychiatric Research and Clinical Practice. OpenAlex counts 14 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Psychiatric Research and Clinical Practice.
- Citations
- 14
- Most cited in
- 2024 (5)
- Field-weighted impact
- 0.45
- References
- 84
- Authors
- 10
Abstract
Objective: The objective of this study was to conduct a systematic review of literature comparing second-generation antipsychotics (SGAs) with each other and with first-generation antipsychotics (FGAs) in treating schizophrenia. Methods: MEDLINE, the Cochrane Library, and PsycINFO databases were searched through January 2020. Following standard methods, recent high-quality systematic reviews of each drug comparison and subsequently published primary studies were included to update the meta-analyses with any new data. Two reviewers independently conducted study selection, abstraction, and quality assessment. Results: Two systematic reviews and 29 newer trials (total of 162 trials of SGAs, N=53,861; 116 trials of SGAs versus FGAs, N=119,558) were included. Most trials were of fair quality, industry-funded, and included older SGAs and a few recently approved SGAs (asenapine, lurasidone, iloperidone, cariprazine, brexpiprazole and long-acting injection [LAI] formulations of aripiprazole and paliperidone). Older SGAs had similar effects on function, quality of life, mortality, and adverse event incidence, although clozapine improved symptoms more than most other drugs and olanzapine and risperidone were superior to some other drugs. Olanzapine, risperidone, ziprasidone, and aripiprazole performed similarly on outcomes of benefit compared with haloperidol. Risperidone LAI and olanzapine resulted in fewer withdrawals due to adverse events, but risk of diabetes increased with olanzapine. Haloperidol had greater incidence of adverse events than did olanzapine and risperidone, but similar effects on other outcomes. Conclusions: Most comparative evidence favored older SGAs, with clozapine, olanzapine, and risperidone superior on more outcomes than other SGAs. Older SGAs had similar benefits as haloperidol but with fewer adverse events.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
McDonagh, M. S., Dana, T., Selph, S., Devine, E. B., Cantor, A. G., Bougatsos, C., Blazina, I., Grusing, S., Fu, R. F., & Haupt, D. W. (2020). Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia. Psychiatric Research and Clinical Practice, 2(2), 76–87. https://doi.org/10.1176/appi.prcp.20200004
MLA 9
McDonagh, Marian S., et al. “Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia.” Psychiatric Research and Clinical Practice, vol. 2, no. 2, 2020, pp. 76–87. https://doi.org/10.1176/appi.prcp.20200004.
Chicago
McDonagh, Marian S., Tracy Dana, Shelley Selph, Emily Beth Devine, Amy G. Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rongwei F. Fu, and Daniel W Haupt. 2020. “Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia.” Psychiatric Research and Clinical Practice 2 (2): 76–87. https://doi.org/10.1176/appi.prcp.20200004.
Harvard
McDonagh, M. S. et al. (2020) ‘Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia’, Psychiatric Research and Clinical Practice, 2(2), pp. 76–87. doi:10.1176/appi.prcp.20200004.
IEEE
M. S. McDonagh et al., “Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia,” Psychiatric Research and Clinical Practice, vol. 2, no. 2, pp. 76–87, 2020, doi: 10.1176/appi.prcp.20200004.
BibTeX
@article{mcdonagh2020updating,
title = {{Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia}},
author = {McDonagh, Marian S. and Dana, Tracy and Selph, Shelley and Devine, Emily Beth and Cantor, Amy G. and Bougatsos, Christina and Blazina, Ian and Grusing, Sara and Fu, Rongwei F. and Haupt, Daniel W},
journal = {Psychiatric Research and Clinical Practice},
year = {2020},
volume = {2},
number = {2},
pages = {76--87},
doi = {10.1176/appi.prcp.20200004},
url = {https://doi.org/10.1176/appi.prcp.20200004}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 2 | |
| 2024 | 5 | |
| 2025 | 1 | |
| 2026 | 5 |
Its field-weighted citation impact is 0.45: it has been cited 0.45 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- atypical antipsychotics
- typical antipsychotics
- schizophrenia
- clozapine
- olanzapine
- risperidone
- haloperidol
- adverse events
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
McDonagh, M. S., Dana, T., Selph, S., Devine, E. B., Cantor, A. G., Bougatsos, C., Blazina, I., Grusing, S., Fu, R. F., & Haupt, D. W. (2020). Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia. Psychiatric Research and Clinical Practice, 2(2), 76–87. https://doi.org/10.1176/appi.prcp.20200004
How many times has this paper been cited?
14 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Psychiatric Research and Clinical Practice: sign in and open the PDF from this page.
Who wrote this paper?
Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily Beth Devine, Amy G. Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rongwei F. Fu, Daniel W Haupt.
What is the DOI of this paper?
10.1176/appi.prcp.20200004, permanently at https://doi.org/10.1176/appi.prcp.20200004. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.